Subaward: Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636]

Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines

R Kalkeri, M Zhu, S Cloney-Clark, JS Plested, A Parekh, D Gorinson, R Cai, S Mahato, P Ramanathan, LC Aurelia, KJ Selva, AM Marchese, L Fries, AW Chung, LM Dunkle

2024-03-01

Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV

M Kang, JC Price, MG Peters, SR Lewin, M Sulkowski

2023-09-01

With growing interest and efforts to achieve a hepatitis B (HBV) cure, HBV therapeutics have increasingly entered the clinical tes..

Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control

A Wedrychowski, HA Martin, Y Li, S Telwatte, GN Kadiyala, M Melberg, B Etemad, E Connick, JM Jacobson, DM Margolis, D Skiest, P Volberding, F Hecht, S Deeks, JK Wong, JZ Li, SA Yukl

2023-01-01

Posttreatment controllers (PTCs) are rare HIV-infected individuals who can limit viral rebound after antiretroviral therapy interr..

Immune biomarkers in the prediction of future myocardial infarctions in people with human immunodeficiency virus

JM Trevillyan, C Moser, JS Currier, T Sallam

2020-04-15

In a retrospective case control analysis, following adjustments for high-sensitivity C-reactive protein (hsCRP), traditional cardi..

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

CD Tweed, AM Crook, R Dawson, AH Diacon, TD McHugh, CM Mendel, SK Meredith, L Mohapi, ME Murphy, AJ Nunn, PPJ Phillips, KP Singh, M Spigelman, SH Gillespie

2019-08-14

Background: The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral t..

Gender differences in tuberculosis treatment outcomes: A post hoc analysis of the REMoxTB study

ME Murphy, GH Wills, S Murthy, C Louw, ALC Bateson, RD Hunt, TD McHugh, AJ Nunn, SK Meredith, CM Mendel, M Spigelman, AM Crook, SH Gillespie, A Diacon, M Hanekom, A Venter, R Dawson, K Narunsky, B Mtafya, N Elias Ntinginya

2018-10-17

Background: In the REMoxTB study of 4-month treatment-shortening regimens containing moxifloxacin compared to the standard 6-month..

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

CD Tweed, AM Crook, EI Amukoye, R Dawson, AH Diacon, M Hanekom, TD McHugh, CM Mendel, SK Meredith, ME Murphy, SE Murthy, AJ Nunn, PPJ Phillips, KP Singh, M Spigelman, GH Wills, SH Gillespie

2018-07-11

Background: The incidence and severity of tuberculosis chemotherapy toxicity is poorly characterised. We used data available from ..

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis

SE Murthy, F Chatterjee, A Crook, R Dawson, C Mendel, ME Murphy, SR Murray, AJ Nunn, PPJ Phillips, KP Singh, TD McHugh, SH Gillespie, A Diacon, M Hanekom, A Venter, K Narunsky, B Mtafya, NE Ntinginya, A Rachow, E Amukoye

2018-05-21

Background: Chest radiographs are used for diagnosis and severity assessment in tuberculosis (TB). The extent of disease as determ..

Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1

MP Martin, V Naranbhai, PR Shea, Y Qi, V Ramsuran, N Vince, X Gao, R Thomas, ZL Brumme, JM Carlson, SM Wolinsky, JJ Goedert, BD Walker, FP Segal, SG Deeks, DW Haas, SA Migueles, M Connors, N Michael, J Fellay

2018-05-01

HLA-B*57 control of HIV involves enhanced CD8+ T cell responses against infected cells, but extensive heterogeneity exists in the ..

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Conor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, Rodney Dawson, Andreas H Diacon, Cheryl E Louw, Timothy D McHugh, Carl Mendel, Sarah Meredith, Lerato Mohapi, Michael E Murphy, Stephen Murray, Sara Murthy, Andrew J Nunn, Patrick PJ Phillips, Kasha Singh, M Spigelman, SH Gillespie

2018-03-28

Background Drug-induced liver injury (DILI) is a common complication of tuberculosis treatment. We utilised data from the REMoxTB ..

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis

ME Murphy, PPJ Phillips, CM Mendel, E Bongard, ALC Bateson, R Hunt, S Murthy, KP Singh, M Brown, AM Crook, AJ Nunn, SK Meredith, M Lipman, TD McHugh, SH Gillespie, A Diacon, M Hanekom, A Venter, R Dawson, K Narunsky

2017-10-27

Background: The use of early morning sputum samples (EMS) to diagnose tuberculosis (TB) can result in treatment delay given the ne..

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy

JZ Li, B Chapman, P Charlebois, O Hofmann, B Weiner, AJ Porter, R Samuel, S Vardhanabhuti, L Zheng, J Eron, B Taiwo, MC Zody, MR Henn, DR Kuritzkes, W Hide, RM Matining, CC Wilson, BI Berzins, EP Acosta, B Bastow

2014-03-06

Background: The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumin..